Cancer Res (2023) 83 (8_Supplement): LB210.
Cancer Res (2022) 82 (22_Supplement): A019.
Cancer Res (2023) 83 (7_Supplement): ND02.
Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ...
1Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts. 2Krantz Family Center for Cancer Research, Massachusetts General ...
1Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland. 2Centre for Haematology, Department of Immunology and Inflammation, Imperial ...
1Guangdong Institute of Gastroenterology, Guangzhou, China.
To help defray the rising costs of initial manuscript screening and publication, the AACR journals levy fees as detailed herein. Authors are required to confirm at the time of submission that they ...
Cancer Res (2019) 79 (13_Supplement): 3278.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results